Navigation Links
Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Date:9/26/2011

GREENWOOD VILLAGE, Colo., Sept. 26, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced positive results from a 12-week open label extension study that was performed at the conclusion of the Phase III trials for Zertane™ in patients with premature ejaculation.  No treatment-related serious adverse events and very few adverse events were recorded during the open-label extension period, when all subjects received active treatment, even though the mean extent of exposure (approximately 0.26 to 0.31 tablets per day) appeared to increase modestly compared to the double-blind treatment period (approximately 0.24 to 0.26 tablets per day). The average use by patients during this 12 week period remained less than 3 pills per week.  Six subjects experienced an adverse event (5.9%) with only one treatment-related adverse event (anxiety/erectile dysfunction), demonstrating that even the higher dose of Zertane™ proves to be safe with a longer follow-up. There were no reports of dependency or tolerability issues.

"These findings of safety during an extended period of time beyond our Phase III clinical trial in men with premature ejaculation help diminish any potential concerns about safety or dependency with the use of the active ingredient of Zertane™," said Don Wingerter, Ampio CEO.

About the Study

The two Phase III trials for Zertane™ were conducted in 62 sites and 11 countries in Europe (results recently published in European Urology). In the open label extension trial, all subjects participating in this study (n=101) received the higher dose of Zertane™ (89 mg), and were evaluated at 3-week intervals for a total of four visits. Safety data col
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
2. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
3. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
4. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
5. Ampio Pharmaceuticals Set to Join Russell 3000 Index
6. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
7. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
8. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
9. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") ... company specializing in personalized medicine, to participate in ... to evaluate the safety and efficacy of HLD-200, ... disorder (ADHD). This is Restore,s second clinical trial ... partnered with Ironshore in 2014 and continues to ...
(Date:8/3/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2015.  Financial and operating highlights for the quarter ... 2015 revenue by 6 percent to $58.9 million, over ... quarter 2015 assay revenue by 22 percent to $24.2 ... , Increased Q2 2015 royalty revenue by 17 ...
(Date:8/3/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today financial results ... million and net loss was $5.5 million for the three ... of $4.6 million and net loss of $5.5 million for ... we had cash and investments of $37.8 million, compared to ... At June 30, 2015, we had $19.8 million in long ...
Breaking Medicine Technology:Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... 31st European Cystic Fibrosis Conference -, SOUTH ... /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) today announced promising ... fibrosis (CF). Results from an Israeli Phase 2a,extension ... in adult,patients with nonsense-mutation-mediated CF demonstrated statistically,significant improvements ...
... Data from Positive Phase 2a Trial, WALTHAM, ... ) today announced that based on feedback from ... initiate a Phase 2b clinical,trial of RG2417, an ... later this year. This will be a multi-center, ...
Cached Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5
(Date:8/4/2015)... , ... August 04, 2015 , ... ... patients whose cancer has come back: Retreatment may be a viable option. Surviving ... read it now. , According to surgeons at the University of New ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin ... unique artistic expressions from a diverse group of exceptionally talented female artists. ... & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated by ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... specializing in healthcare finance, announced the closing of a $118 million FHA-insured loan ... health system located in Smithfield and Clayton, North Carolina. JHSC is a ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a ... Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were published on June ... According to the results of the trial, the implant, more commonly known as the ...
(Date:8/4/2015)... ... , ... Centurion Service Group, the world's largest medical equipment auction house, will ... The live auction will take place on Thursday, August 6 beginning at ... 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2
... risks from prescription drugs, survey suggests , THURSDAY, July ... link between pop star Michael Jackson,s death and his ... public,s concern about prescription medication overdose risks, suggests a ... 200 respondents who work in home, ambulatory and chronic ...
... healthcare reform a high priority on the national agenda, Shan ... leading provider of Health Management Solutions, believes the market is ... down costs while also improving healthcare quality for all Americans. ... ) , , "Despite a down economy, health ...
... CHICAGO, July 9 In these amazing times, with real ... are endless for registered dietitians in keeping the public we ... Dietetic Association,s key tenets is that every American has a ... and that this right includes access to healthy food from ...
... Carriage Services, Inc. (NYSE: CSV ) today announced plans ... after the market closes. In conjunction with the release, Carriage ... over the Internet, for Friday, July 31, 2009 at 10:30 a.m. ... Carriage Services Second Quarter 2009 Earnings Conference Call, ...
... SANTA MONICA, Calif. and LAS VEGAS, July 9 Cord ... largest umbilical cord blood stem cell preservation companies ( ... saving potential of stem cells to families nationwide and internationally, ... square foot building in Las Vegas, Nevada, for a state-of-the-art ...
... ... and Germicidal UV Modules from healthcare facilities as they activate their emergency pandemic ... ... strong demand for their HEPA-CARE® Air Filtration Systems and Germicidal UV Modules from ...
Cached Medicine News:Health News:Questions to Pharmacists Rise After Michael Jackson's Death 2Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 2Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 3Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 4Health News:Health Plans Continue to Select Health Integrated to Improve Member Health, Reduce Costs 5Health News:Statement by Registered Dietitian and American Dietetic Association President Jessie M. Pavlinac on Health Reform and Conservation of Natural Resources 2Health News:Carriage Services Announces Second Quarter Earnings Release and Conference Call Schedule 2Health News:Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 2Health News:Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 3Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 3
... perfused manometric catheters for esophageal, ... tests. All Medtronic Water Perfused ... medical grade PVC tubing. For ... you will find a number ...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
... We have water perfused manometric ... vector volume diagnostic tests. All ... made using clear, medical grade ... in the esophagus you will ...
Replacement Stopper for LATITUDE® Air-Charged Catheter...
Medicine Products: